Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;25(9):2665-72.
doi: 10.1007/s00330-015-3688-1. Epub 2015 Mar 29.

Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI

Andreas M Hötker  1 , Yousef Mazaheri, Junting Zheng, Chaya S Moskowitz, Joshua Berkowitz, Joshua E Lantos, Xin Pei, Michael J Zelefsky, Hedvig Hricak, Oguz Akin
Affiliations

Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI

Andreas M Hötker et al. Eur Radiol. 2015 Sep.

Abstract

Purpose: To investigate the effects of androgen-deprivation therapy (ADT) on MRI parameters and evaluate their associations with treatment response measures.

Materials and methods: The study included 30 men with histopathologically confirmed prostate cancer who underwent MRI before and after initiation of ADT. Thirty-four tumours were volumetrically assessed on DW-MRI (n = 32) and DCE-MRI (n = 18), along with regions of interest in benign prostatic tissue, to calculate apparent diffusion coefficient (ADC) and transfer constant (K(trans)) values. Changes in MRI parameters and correlations with clinical parameters (change in prostate-specific antigen [PSA], treatment duration, PSA nadir) were assessed.

Results: Prostate volume and PSA values decreased significantly with therapy (p < 0.001). ADC values increased significantly in tumours and decreased in benign prostatic tissue (p < 0.05). Relative changes in ADC and absolute post-therapeutic ADC values differed significantly between tumour and benign tissue (p < 0.001). K(trans) decreased significantly only in tumours (p < 0.001); relative K(trans) changes and post-therapeutic values were not significantly different between tumour and benign tissue. The relative change in tumour ADC correlated significantly with PSA decrease. No changes were associated with treatment duration or PSA nadir.

Conclusions: Multi-parametric MRI shows significant measurable changes in tumour and benign prostate caused by ADT and may help in monitoring treatment response.

Key points: • Androgen-deprivation therapy caused changes of ADC, K (trans) in tumour and benign prostate. • Prostate volume and PSA values decreased significantly with therapy. • ADC values may be helpful for monitoring treatment response.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a-f: Sixty-eight-year-old man with histopathologically-proven prostate cancer (Gleason score 4+4) who had MRI examinations before (a-c) and after the start (d-f) of androgen-deprivation therapy: (a/d) T2-weighted images, (b/e) ADC maps (b = 1000 s/mm2), (c/f) T1-weighted dynamic contrast-enhanced MR images.
Fig. 1
Fig. 1
a-f: Sixty-eight-year-old man with histopathologically-proven prostate cancer (Gleason score 4+4) who had MRI examinations before (a-c) and after the start (d-f) of androgen-deprivation therapy: (a/d) T2-weighted images, (b/e) ADC maps (b = 1000 s/mm2), (c/f) T1-weighted dynamic contrast-enhanced MR images.
Fig. 1
Fig. 1
a-f: Sixty-eight-year-old man with histopathologically-proven prostate cancer (Gleason score 4+4) who had MRI examinations before (a-c) and after the start (d-f) of androgen-deprivation therapy: (a/d) T2-weighted images, (b/e) ADC maps (b = 1000 s/mm2), (c/f) T1-weighted dynamic contrast-enhanced MR images.
Fig. 1
Fig. 1
a-f: Sixty-eight-year-old man with histopathologically-proven prostate cancer (Gleason score 4+4) who had MRI examinations before (a-c) and after the start (d-f) of androgen-deprivation therapy: (a/d) T2-weighted images, (b/e) ADC maps (b = 1000 s/mm2), (c/f) T1-weighted dynamic contrast-enhanced MR images.
Fig. 1
Fig. 1
a-f: Sixty-eight-year-old man with histopathologically-proven prostate cancer (Gleason score 4+4) who had MRI examinations before (a-c) and after the start (d-f) of androgen-deprivation therapy: (a/d) T2-weighted images, (b/e) ADC maps (b = 1000 s/mm2), (c/f) T1-weighted dynamic contrast-enhanced MR images.
Fig. 1
Fig. 1
a-f: Sixty-eight-year-old man with histopathologically-proven prostate cancer (Gleason score 4+4) who had MRI examinations before (a-c) and after the start (d-f) of androgen-deprivation therapy: (a/d) T2-weighted images, (b/e) ADC maps (b = 1000 s/mm2), (c/f) T1-weighted dynamic contrast-enhanced MR images.
Fig. 2
Fig. 2
a/b: Plots for ADC (mm2/s) and Ktrans (min−1) values before (pre) and after the start (post) of androgen-deprivation therapy for each individual patient, stratified by peripheral zone (PZ), transition zone (TZ) and tumour.
Fig. 2
Fig. 2
a/b: Plots for ADC (mm2/s) and Ktrans (min−1) values before (pre) and after the start (post) of androgen-deprivation therapy for each individual patient, stratified by peripheral zone (PZ), transition zone (TZ) and tumour.
See this image and copyright information in PMC

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. - PubMed
    1. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451–9. - PubMed
    1. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85–31. J Clin Oncol. 2005;23(4):800–7. - PubMed
    1. Chen M, Hricak H, Kalbhen CL, Kurhanewicz J, Vigneron DB, Weiss JM, et al. Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. AJR Am J Roentgenol. 1996;166(5):1157–63. - PubMed
    1. Mueller-Lisse UG, Vigneron DB, Hricak H, Swanson MG, Carroll PR, Bessette A, et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology. 2001;221(2):380–90. - PubMed

Publication types

Substances